EDESA BIOTECH, INC.
19.99%
2,040,785
1540159
27966L306
Feb 25, 2026
Mar 2, 2026, 05:11 PM
Reporting Persons (5)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Pardeep Nijhawan | Individual | 19.99% | 2,040,785 | 789,383 | 1,251,402 |
| Pardeep Nijhawan Medicine Professional Corporation | CO | 11.90% | 1,133,676 | 0 | 1,133,676 |
| 1968160 Ontario Inc. | CO | 0.60% | 53,104 | 0 | 53,104 |
| The Digestive Health Clinic Inc. | CO | 0.40% | 32,013 | 0 | 32,013 |
| The New Nijhawan Family Trust 2015 | Other | 0.40% | 32,609 | 0 | 32,609 |
Disclosure Items (4)
Common Shares, no par value per share
EDESA BIOTECH, INC.
100 Spy Court, Markham, A6, L3R 5H6
Item 3 is hereby supplemented as follows: Since the filing of the Schedule 13D/A on February 14, 2025, the Issuer has granted Dr. Pardeep Nijhawan the following restricted stock units, which vested in full upon grant: (i) 6,339 restricted stock units on March 3, 2025, (ii) 5,784 restricted stock units on April 1, 2025, (iii) 6,392 restricted stock units on May 2, 2025, (iv) 7,644 restricted stock units on June 2, 2025, (v) 7,186 restricted stock units on July 2, 2025, (vi) 6,802 restricted stock units on August 1, 2025, (vii) 5,981 restricted stock units on September 11, 2025, (viii) 5,908 restricted stock units on October 2, 2025, (ix) 6,968 restricted stock units on November 3, 2025, (x) 8,766 restricted stock units on December 1, 2025, (xi) 10,444 restricted stock units on January 5, 2026, (xii) 11,168 restricted stock units on February 2, 2026, (xiii) 82,236 restricted stock units on February 19, 2026, and (xiv) 10,016 restricted stock units on March 2, 2026. Such restricted stock units were granted in lieu of partial salary and bonus. On May 29, 2025, granted Dr. Pardeep Nijhawan 263,200 restricted stock units of which (i) 166,287 shares shall vest monthly in equal proportions over twelve (12) months, commencing on the grant date and (ii) 96,913 shares shall vest in equal proportions over thirty-six (36) months, commencing on the grant date. On February 26, 2026, Dr. Pardeep Nijhawan purchased an aggregate of 20,571 Common Shares at a weighted average price of $1.5789 per share for an aggregate purchase price of $32,479.34. Dr. Pardeep Nijhawan purchased the Common Shares with investment capital. On February 26, 2026, Pardeep Nijhawan Medicine Professional Corporation purchased an aggregate of 30,000 Common Shares at a weighted average price of $2.2232 per share for an aggregate purchase price of $66,695.00. Pardeep Nijhawan Medicine Professional Corporation purchased the Common Shares with investment capital.
As of the date hereof, Pardeep Nijhawan may be deemed to be the beneficial owner of an aggregate of 2,040,785 Common Shares, comprised of: (i) sole voting and dispositive power of 789,383 Common Shares, comprised of: (a) 105,544 Common Shares, (b) 439,090 Common Shares underlying vested restricted stock units or restricted stock units that will vest within 60 days of March 2, 2026, (c) 55,916 Common Shares underlying vested share options or underlying share options that will vest within 60 days of March 2, 2026 and (d) 188,833 Common Shares underlying Series B-1 Preferred Shares that are beneficially owned and deemed outstanding with respect to this Reporting Person; and (ii) shared voting and dispositive power of 1,251,402 Common Shares, comprised of: (a) 371,702 Common Shares, an additional 326,560 Common Shares underlying vested warrants and 435,414 Common Shares underlying Series A-1 Preferred Shares that are deemed outstanding held by Pardeep Nijhawan Medicine Professional Corporation, (b) 32,013 Common Shares held by The Digestive Health Clinic Inc., (c) 53,104 Common Shares held by 1968160 Ontario Inc., and (d) 32,609 Common Shares held by The New Nijhawan Family Trust 2015. Pardeep Nijhawan's holdings exclude Common Shares underlying Series B-1 Preferred Shares held by Pardeep Nijhawan which are subject to a 19.99% beneficial ownership blocker, Common Shares underlying restricted stock units held by this Reporting Person that will not vest within 60 days of March 2, 2026 and Common Shares underlying share options held by this Reporting Person that will not vest within 60 days of March 2, 2026. The Reporting Person will not have the right to convert any portion of its Series B-1 Preferred Shares if, together with its affiliates, it would beneficially own in excess of 19.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. Pardeep Nijhawan's holdings represent an aggregate of approximately 19.99% of the Issuer's outstanding Common Shares (based on a total of 8,764,826 Common Shares of the Issuer outstanding as of March 2, 2026, 55,916 Common Shares underlying vested share options or underlying share options that will vest within 60 days of March 2, 2026, 439,090Common Shares underlying vested restricted stock units or restricted stock units that will vest within 60 days of March 2, 2026, 326,560 Common Shares underlying vested warrants, 435,414 Common Shares underlying Series A-1 Preferred Shares and 188,833Common Shares underlying Series B-1 Preferred Shares that are beneficially owned and deemed outstanding with respect to this Reporting Person). As of the date hereof, Pardeep Nijhawan Medicine Professional Corporation may be deemed to be the beneficial owner, with shared voting and dispositive power, of an aggregate of 1,133,676 Common Shares, comprised of: (i) 371,702 Common Shares, (ii) 326,560 Common Shares underlying vested warrants and (iii) 435,414 Common Shares underlying Series A-1 Preferred Shares that are deemed outstanding with respect to this Reporting Person. Pardeep Nijhawan Medicine Professional Corporation's holdings represent an aggregate of approximately 11.9% of the Issuer's outstanding Common Shares (based on a total of 8,764,826 Common Shares of the Issuer outstanding as of March 2, 2026, 326,560 Common Shares underlying vested warrants and 435,414 Common Shares underlying Series A-1 Preferred Shares that are deemed outstanding with respect to this Reporting Person). As of the date hereof, The Digestive Health Clinic Inc. may be deemed to be the beneficial owner, with shared voting and dispositive power, of 32,013 Common Shares, representing an aggregate of approximately 0.4% of the Issuer's outstanding Common Shares (based on a total of 8,764,826 Common Shares of the Issuer outstanding as of March 2, 2026). As of the date hereof, 1968160 Ontario Inc. may be deemed to be the beneficial owner, with shared voting and dispositive power, of 53,104 Common Shares, representing an aggregate of approximately 0.6% of the Issuer's outstanding Common Shares (based on a total of 8,764,826 Common Shares of the Issuer outstanding as of March 2, 2026). As of the date hereof, The New Nijhawan Family Trust 2015 may be deemed to be the beneficial owner, with shared voting and dispositive power, of 32,609 Common Shares, representing an aggregate of approximately 0.4% of the Issuer's outstanding Common Shares (based on a total of 8,764,826 Common Shares of the Issuer outstanding as of March 2, 2026).
The information contained in Item 5(a) of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 5(b).
Except as set forth in this Schedule 13D, the Reporting Persons have not effected any transactions with respect to the Common Shares of the Issuer during the past 60 days.